Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM).

Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) [1]. Mavorixafor (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells [2].

Mavorixafor (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice and lowers the expression of human Alu DNA in mice without body weight loss [2].

2309699-17-8

C21H30Cl3N5

458.86

AMD-070 trihydrochloride

DMSO:6 mg/mL (13.08 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years